These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30549487)

  • 61. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Initial severity of the Positive and Negative Syndrome Scale (PANSS)-30, its main subscales plus the PANSS-6, and the relationship to subsequent improvement and trial dropout: a pooled participant-level analysis of 18 placebo-controlled risperidone and paliperidone trials.
    Hieronymus F; Correll CU; Østergaard SD
    Transl Psychiatry; 2023 Jun; 13(1):191. PubMed ID: 37286548
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
    Alphs L; Bossie CA; Fu DJ; Ma YW; Kern Sliwa J
    Expert Opin Pharmacother; 2014 May; 15(7):1029-42. PubMed ID: 24754314
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
    Marder SR; Kramer M; Ford L; Eerdekens E; Lim P; Eerdekens M; Lowy A
    Biol Psychiatry; 2007 Dec; 62(12):1363-70. PubMed ID: 17601495
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
    Citrome L; Meng X; Hochfeld M
    Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Does Half-Life Matter After Antipsychotic Discontinuation? A Relapse Comparison in Schizophrenia With 3 Different Formulations of Paliperidone.
    Weiden PJ; Kim E; Bermak J; Turkoz I; Gopal S; Berwaerts J
    J Clin Psychiatry; 2017 Jul; 78(7):e813-e820. PubMed ID: 28640988
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.
    Ivaturi V; Gopalakrishnan M; Gobburu JVS; Zhang W; Liu Y; Heidbreder C; Laffont CM
    Br J Clin Pharmacol; 2017 Jul; 83(7):1476-1498. PubMed ID: 28133766
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia.
    Krekels E; Novakovic AM; Vermeulen AM; Friberg LE; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2017 Aug; 6(8):543-551. PubMed ID: 28571119
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia.
    Targum SD; Risinger R; Du Y; Pendergrass JC; Jamal HH; Silverman BL
    Schizophr Res; 2017 Jan; 179():64-69. PubMed ID: 27707530
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial.
    Findling RL; McKenna K; Earley WR; Stankowski J; Pathak S
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):327-42. PubMed ID: 23083020
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
    Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Association between discontinuation due to withdrawal of consent and use of long-acting injectable antipsychotics: A meta-analysis of randomized trials for schizophrenia.
    Kishi T; Sakuma K; Okuya M; Iwata N
    J Psychiatr Res; 2021 Jan; 132():144-150. PubMed ID: 33096355
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.
    Huang M; Yu L; Pan F; Lu S; Hu S; Hu J; Chen J; Jin P; Qi H; Xu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():122-130. PubMed ID: 29097257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.